The research confirmed no abnormal dangers, which indicated that it could be properly administered inside of a medical research context. Later on, Dr. Charles Grob asked for authorization to further study the compound with cancer individuals, but was denied because of the FDA twice.The first report of the synthesis of copyright while in the peer-re